SAD-PD

SAD-PD

• 批准号: 7378892
• 负责人: LAURA MARSH
• 金额: $ 0.03万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2005
• 资助国家: 美国
• 起止时间: 2005-12-01 至 2006-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7378892
• 关键词: SAD; PD

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Depression is common in patients with Parkinson's disease (PD) and is a major factor negatively impacting quality of life. To date there have been no well-designed clinical trials of antidepressant pharmacotherapy for depression in PD. Selective serotonin reuptake inhibitor (SSRI) and, more recently, combined serotonin and norepinephrine reuptake inhibitor (SNRI) antidepressants are used as first-line treatment for depression. However, their efficacy and tolerability in PD have not been established and there are several important reasons why results from studies in primary psychiatric populations cannot simply be extrapolated to patients with PD. In PD, the underlying pathophysiology and somewhat atypical depressive features may result in a different antidepressant response. Furthermore, PD patients are particularly vulnerable to antidepressant-induced extrapyramidal side effects and a host of factors (including concomitant antiparkinsonian medications) that may affect the general tolerability of these agents. The proposed clinical trial has been designed to evaluate the efficacy and tolerability of paroxetine (an SSRI) and venlafaxine extended release (an SNRI) in PD patients with depression. Information regarding the effects of these medications on motor function, quality of life and cognition will also be obtained. Two hundred twenty-eight subjects will be enrolled among 16 centers and each subject will participate in the trial for 12 weeks. The trial will clarify many important questions regarding the treatment of depression in patients with PD.

该子项目是利用 NIH/NCRR 资助的中心拨款提供的资源的众多研究子项目之一。子项目和研究者 (PI) 可能已从另一个 NIH 来源获得主要资金，因此可以在其他 CRISP 条目中得到体现。列出的机构是中心的机构，不一定是研究者的机构。抑郁症在帕金森病 (PD) 患者中很常见，是对生活质量产生负面影响的主要因素。迄今为止，还没有针对 PD 抑郁症的抗抑郁药物治疗进行精心设计的临床试验。选择性血清素再摄取抑制剂（SSRI）以及最近的复合血清素和去甲肾上腺素再摄取抑制剂（SNRI）抗抑郁药被用作抑郁症的一线治疗。然而，它们对帕金森病的疗效和耐受性尚未确定，并且有几个重要原因导致初级精神病人群的研究结果不能简单地外推到帕金森病患者。在帕金森病中，潜在的病理生理学和有些非典型的抑郁特征可能会导致不同的抗抑郁反应。此外，帕金森病患者特别容易受到抗抑郁药引起的锥体外系副作用和许多可能影响这些药物总体耐受性的因素（包括伴随的抗帕金森病药物）的影响。 拟议的临床试验旨在评估帕罗西汀（一种 SSRI）和文拉法辛缓释剂（一种 SNRI）对 PD 抑郁症患者的疗效和耐受性。还将获得有关这些药物对运动功能、生活质量和认知的影响的信息。 16个中心将招募228名受试者，每位受试者将参加为期12周的试验。 该试验将澄清有关 PD 患者抑郁症治疗的许多重要问题。